Goudi Lvlei Tading Pian (枸地氯雷他定片)枸地氯雷他定片
This is a medicine registration record from NMPA data.本页为国家药监局药品注册记录。
Labeled sections from the recorded Chinese source are included below. English wording is a reference translation when one is on file, not an official English label.本记录未接入产品级适应症/安全性标注字段。
生产企业Manufacturer
- 扬子江药业集团广州海瑞药业有限公司Chinese legal name: 扬子江药业集团广州海瑞药业有限公司
主要成分Active Ingredients
- 地氯雷他定Dilv Leita Ding
- 环庚Huan Geng
- b]吡啶
药物知识说明
地氯雷他定是一种在国家药监局注册认定的药品。该药品含有相关活性成分。
该药品关联的活性成分包括：b]吡啶Bi Ding、地氯雷他定Dilv Leita Ding。这些成分信息来自国家药监局数据库。
您可以探索含有相同成分的其他药品：b]吡啶-67e9a12c成分药品。
本页面内容来自国家药监局数据库，MedicineGraph在此基础上提供关系图谱和知识导航。
Medicine Knowledge
This medicine (original name: 枸地氯雷他定片) is a medicine registered with the national drug regulatory authority. It contains active ingredient(s) as recorded.
Active ingredients associated with this product: b]吡啶Bi Ding, 地氯雷他定Dilv Leita Ding.
Explore other medicines containing the same ingredient: b]吡啶 productsProducts containing this recorded ingredient.
Source: MedicineGraph authoritative database. Relationships derived from registered product information.
这是什么What is this
- 通用名/品名Recorded product name: 枸地氯雷他定片Recorded Chinese name: 枸地氯雷他定片
- 剂型Dosage form: 片剂Tablets
- 规格Specification: 8.8mg*6片8.8 mg × 6 tablets
本段仅展示注册/说明书已记录的身份属性，不含适应症或用法建议。Identity attributes from registration/leaflet records only; no indications or usage advice.
主要成分Ingredients
生产企业Manufacturer
- 扬子江药业集团广州海瑞药业有限公司Chinese legal name: 扬子江药业集团广州海瑞药业有限公司
注册信息NMPA approval number
- 批准文号NMPA approval number: 国药准字H20090138
关联实体Relationships
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据及已接入说明书字段。National Medical Products Administration (China) medicine-registration data and linked leaflet fields.
- 品名来源Name source: 10多万条药品说明书数据库 (HIGH)Package-insert database (more than 100,000 records) (HIGH)
- 生产企业来源Manufacturer source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
- 剂型来源Dosage-form source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。不含适应症/安全性推断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence. No inferred indications/safety.
本段为已核准说明书原文摘录（非改写、非AI摘要），非正式英文标签，亦不构成用药建议。 Not an official English label and not medical advice. English wording, when shown, is a reference translation of the Chinese source label.
English translation for reference. Translated from the Chinese source label. Not an official English label and not medical advice.
NMPA approval number
国药准字H20090138
Manufacturer
Chinese legal name: 扬子江药业集团广州海瑞药业有限公司 (domestically manufactured)
Indications
English translation unavailable. The original Chinese source label remains available below.
Dosage and administration
English translation unavailable. The original Chinese source label remains available below.
Adverse reactions
English translation unavailable. The original Chinese source label remains available below.
Contraindications
English translation unavailable. The original Chinese source label remains available below.
Precautions
English translation unavailable. The original Chinese source label remains available below.
Storage
English translation unavailable. The original Chinese source label remains available below.
Specification
8.8 mg × 6 tablets
中文说明书原文Original Chinese source label
批准文号
国药准字H20090138
生产企业
扬子江药业集团广州海瑞药业有限公司(国产)
适应症
1.本品用于快速缓解过敏性鼻炎的相关症状，如打喷嚏，流涕和鼻痒、鼻粘膜充血，鼻塞；以及眼痒、流泪和充血；腭痒及咳嗽。 2.本品还用于缓解慢性特发性荨麻疹的相关症状如瘙痒，并可减少荨麻疹的数量及大小。
用法用量
成人及12岁或12岁以上的青少年：口服，每日一次，每次1片。进食不影响服药效果。
不良反应
1.在一系列以过敏性鼻炎和慢性特发性荨麻疹为适应症的临床试验中，患者按每天5毫克的推荐剂量服用地氯雷他定，试验组不良反应发生率比安慰剂组高3%。
2.超过安慰剂组的最常见不良反应为疲倦(1.2%)、口干(0.8%)和头痛(0.6%)。
3.在地氯雷他定上市后罕有过敏性反应报道，包括过敏和皮疹。
4.另外罕有心动过速、心悸、肝酶升高及胆红素增加的报道。
禁忌
对本品活性成份或赋形剂过敏者禁用。
注意事项
1.由于抗组胺药能清除或减轻皮肤对所有变应原的阳性反应，因而在进行任何皮肤性实验前48小时，应停止使用本品。
2.肝功能不良、膀胱颈阻塞或尿潴留，尿道张力过强，前列腺肥大、青光眼患者应遵医嘱用药。
3.若发生嗜睡或头晕，请避免开车和操作机器。
4.严重肾功能不全患者慎用。
贮藏
密封，在干燥处保存。
规格
8.8mg*6片
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据。National Medical Products Administration (China) medicine-registration data.
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence.